source
- Disc Medicine's rare sun-sensitivity drug meets all endpoints in Phase 3 trialDisc Medicine announced that its experimental therapy for a rare condition that makes sun exposure painful has completed a Phase 3 study. The trial reported success on every primary and secondary…
- Nonprofit arbitrators under No Surprises Act earning large profits, investigation findsA recent STAT investigation examined the role of nonprofit organizations that serve as arbitrators under the No Surprises Act. The report found that these entities are generating substantial revenu…